Biophytis SA announces the full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia that have been presented at the International Conference on Frailty and Sarcopenia Research (ICFSR) on September, 30th. ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field. The results of SARA-INT, with safety and efficacy endpoints including subgroup analysis and secondary endpoints, have been presented by Cendrine Tourette, PhD Biophytis SARA Project Leader and discussed during a dedicated session, moderated by Waly Dioh PhD, Biophytis Chief Operations Officer and Roger A. Fielding, PhD, Principal Investigator of the SARA-INT trial, who heads the Nutrition, Exercise Physiology & Sarcopenia team at Tufts University in Boston. The effect of two doses of Sarconeos (BIO101), 175 mg bid and 350 mg bid, have been compared to placebo in the Full Analysis Dataset (FAS) and in the Per-Protocol population (PP, subset of participants that complied to the clinical protocol), as well as in sub-populations of patients. Sarconeos (BIO101) at the dose of 350 mg bid showed a clinically meaningful improvement of 0.09 m/s in the FAS population (not significant) and of 0.10 m/s in the PP population (significant, p=0.008) compared to placebo (observed data), for the 400MWT in gait speed after 6 months of treatment. This effect is close to the Minimal Clinically Important Difference (MCID) in sarcopenia (0.1 m/s) known to be associated with a reduction in mobility disability and mortality in elderly. Sarconeos (BIO101) at 350mg bid showed very promising treatment effect on the 400MWT gait speed in sub-population at higher risk of mobility disability such as slow walkers (0.07 m/s, p = 0.015 in PP population), obese subgroup (0.09 m/s, p= 0.004 in PP population), chair stand sub-score =2 of the SPPB (0,09 m/s, p= 0.004 in PP population). A trend towards a dose-dependent effect, although not significant, was observed, on the following secondary endpoints: Handgrip Strength and 6-Minute Walk Distance (6MWD) test. Further analyses, e.g. on correlations between clinical endpoints and other parameters, biomarkers and actimetry are ongoing and will be communicated later in scientific congresses.